Key result
Pazopanib yields 5-month progression-free survival in a patient with refractory lung Ewing's sarcoma.
Why the study?
Ewing's sarcoma/primitive neuroectodermal tumors of the lung are very rare and associated with a poor prognosis.
Does pazopanib improve progression-free survival in a patient with recurrent Ewing's sarcoma/primitive neuroectodermal tumor of the lung?
Case Report (n=1)
Does pazopanib improve progression-free survival in a patient with recurrent Ewing's sarcoma/primitive neuroectodermal tumor of the lung?
Pazopanib may offer progression-free survival benefits in patients with recurrent Ewing's sarcoma/primitive neuroectodermal tumor of the lung.
May offer salvage option in refractory pulmonary Ewing sarcoma; leaves open need for prospective trials before any practice change.
Ewing's sarcoma (ES)/primitive neuroectodermal tumors (PNETs) are highly malignant neoplasms that usually affect the bones and soft tissues in children and young adults. ES/PNET of the lung is very rare and is associated with a poor prognosis. We herein report a case of ES/PNET of the left lung in a 45-year-old man. He was treated with neoadjuvant chemotherapy and pneumonectomy, but unfortunately his disease recurred 1.5 months after surgery. He was started on pazopanib, which resulted in a five-month progression-free survival. To our knowledge, this is the first demonstration of pazopanib efficacy in ES/PNET of the lung.
No takes yet. Share an insight, caveat, or question.
Takigami et al. (2019) conducted a case report in Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) of the lung (n=1). Pazopanib was evaluated on Progression-free survival. Pazopanib treatment resulted in a five-month progression-free survival in a patient with refractory Ewing's sarcoma/primitive neuroectodermal tumor of the lung.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: